Senate Hearing On Ozempic, Wegovy Highlights Concerns About PBMs, International Price Disparities

Senate HELP Committee chair Sanders trying to broker a deal between Novo Nordisk and the major pharmacy benefit managers that will lead to lower list prices.

More from Pricing Debate

More from PBMs